Liliane Kheng, MD
Internal Medicine · Lihue, HINPI 1285639104
Payments from drug & device makers
Across 187 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$342
- Novo Nordisk$308
- Sanofi-aventis U.S. LLC$305
- Pfizer$242
- Lilly USA, LLC$213
- Amgen$206
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,00899%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $342 |
| Novo Nordisk | 26 | $308 |
| Sanofi-aventis U.S. LLC | 17 | $305 |
| Pfizer | 18 | $242 |
| Lilly USA, LLC | 22 | $213 |
| Amgen(2 entities) | 10 | $206 |
| Boehringer Ingelheim | 8 | $182 |
| GSK | 13 | $176 |
| Insmed, Inc. | 3 | $162 |
| AbbVie(2 entities) | 8 | $145 |
| Merck | 6 | $114 |
| Johnson & Johnson | 5 | $100 |
| Novartis | 5 | $90 |
| E.r. Squibb & Sons, L.L.C. | 6 | $85 |
| Teva Pharmaceuticals USA, Inc. | 5 | $77 |
| Abbott | 3 | $59 |
| Astellas Pharma US Inc | 2 | $44 |
| Amarin Pharma, Inc. | 2 | $40 |
| Ironwood Pharmaceuticals, Inc | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Nestle Healthcare Nutrition Inc. | 2 | $28 |
| Radius Health, Inc. | 1 | $27 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$3,043 in reported general payments places this provider in the 80th percentile of 655 internal medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 277 | $322,944 |
| OzempicSemaglutide | 206 | $239,238 |
| EliquisApixaban | 111 | $101,654 |
| ProliaDenosumab | 50 | $86,399 |
| MounjaroTirzepatide | 79 | $83,964 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 42 | $58,234 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $50,475 |
| RybelsusSemaglutide | 22 | $45,418 |
| XareltoRivaroxaban | 42 | $43,740 |
| CreonLipase/Protease/Amylase | 20 | $39,207 |
| TymlosAbaloparatide | 13 | $35,360 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $26,934 |
| Rosuvastatin Calcium | 621 | $24,816 |
| EntrestoSacubitril/Valsartan | 28 | $22,447 |
| JanuviaSitagliptin Phosphate | 11 | $17,691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Combivent Respimat | $182 | $405,165354 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy | $308 | $300,621240 claims |
| PfizerEliquis, Paxlovid | $242 | $104,373123 claims |
| Lilly USA, LLCMounjaro, Trulicity | $213 | $97,92990 claims |
| AmgenProlia | $206 | $86,39950 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $176 | $57,96287 claims |
| Johnson & JohnsonXarelto | $100 | $43,74042 claims |
| AbbVieCreon | $145 | $39,20720 claims |
| Radius Health, Inc.Tymlos | $27 | $35,36013 claims |
| MerckJanuvia, Janumet | $114 | $34,37324 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $342 | $34,20360 claims |
| NovartisEntresto | $90 | $22,44728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 655 internal medicine providers in Hawaii.
Other internal medicine in Lihue
- Michael BraunLihue$9K
- Michael SavonaWailuku$520K
- Scott StromattKamuela$385K
- Keith WooHonolulu$106K
- Ronald PerryHonolulu$102K
- Laurie TomHonolulu$95K
- Yusuke MiyataniHonolulu$80K
- Joshua TanHonolulu$76K
- Jose de LeonHonolulu$52K
- Peter DeeHonolulu$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.